Business Context and Reporting Period
This Form 8-K is a current report filed by AcelRx Pharmaceuticals, Inc. (not TalpherA, Inc.) on August 19, 2015. The filing addresses a change in the registrant's certifying accountants for the fiscal year ending December 31, 2015.
Key Financial Metrics
This filing does not contain financial performance data. There are no reported figures for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
- Dismissal of Auditor: The Audit Committee dismissed Ernst & Young LLP (E&Y) effective immediately on August 19, 2015.
- Engagement of New Auditor: OUM & Co. LLP was engaged on August 20, 2015, as the independent registered public accounting firm for the fiscal year ending December 31, 2015.
- Audit History: E&Y's reports for fiscal years 2013 and 2014 contained no adverse opinions, disclaimers, or qualifications. There were no disagreements with E&Y regarding accounting principles, practices, or audit scope during the two most recent fiscal years or the interim period through August 19, 2015.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business operations. The primary disclosure relates to the procedural change in audit firms. The company confirmed that no "reportable events" occurred under Regulation S-K Item 304(a)(1)(v) during the relevant period. OUM & Co. LLP reviewed the filing and submitted no letter to the SEC indicating disagreement or additional information.
Investor Verification Checklist
- Verify the rationale for dismissing Ernst & Young LLP, as the filing states the change resulted from a competitive process but does not detail specific reasons.
- Confirm the qualifications and experience of the new auditor, OUM & Co. LLP, for a pharmaceutical company.
- Review the attached Exhibit 16.1 (Letter from Ernst & Young LLP) for any additional context not summarized in the main text.
- Monitor upcoming filings (e.g., 10-Q or 10-K) to ensure the transition of auditors does not impact the timeliness or quality of future financial reporting.